½ÃÀ庸°í¼­
»óǰÄÚµå
1370949

ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå : ¼¼°è »ê¾÷ ±Ô¸ð, µ¿Çâ, ±âȸ, ¿¹Ãø(2018-2028³â) - Á¦Ç° À¯Çüº°, °Ë»ç À¯Çüº°, Áúȯ À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°, °æÀï

Autoimmune Disease Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Test Type, By Disease Type, By End User, By Region and Competition

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: TechSci Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 189 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀåÀº 2022³â¿¡ 50¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç ¿¹Ãø ±â°£ Áß °­·ÂÇÑ ¼ºÀåÀ» º¸À̸ç, ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR) 6.37%¸¦ ¿¹ÃøÇϸç, 2028³â¿¡´Â 72¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

ÀÚ°¡¸é¿ªÁúȯ(AD)Àº °Ç°­ÇÑ ¸é¿ªÇÐÀû ±ÕÇüÀÇ ºØ±«¸¦ Ư¡À¸·Î ÇÏ´Â ºñ°¨¿°¼º ÁúȯÀ¸·Î, °¨¿°µÈ Á¶Á÷ ¼¼Æ÷¿¡¼­ ºñÁ¤»óÀûÀÎ ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â ÁúȯÀÔ´Ï´Ù. ¿°Áõ, ÀÚ°¡Ç×ü, Ȱ¼ºÈ­µÈ T¼¼Æ÷´Â ÀÚ°¡¸é¿ªÁúȯÀÇ ¹ßº´¿¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀϹÝÀûÀ¸·Î ¸é¿ª¼¼Æ÷´Â ¹ÚÅ׸®¾Æ³ª ¹ÙÀÌ·¯½º¿Í °°Àº ¿ÜºÎ º´¿øÃ¼¸¦ ÀνÄÇϰí ÀÌ¿¡ ´ëÇ×ÇÏÁö¸¸, ÀÚ°¡¸é¿ªÁúȯÀº ¸é¿ªÃ¼°è°¡ À߸øÇÏ¿© ½Åü ÀÚü¸¦ °ø°ÝÇÏ´Â ÁúȯÀÔ´Ï´Ù. ÀϺΠÀÚ°¡¸é¿ªÁúȯÀº ƯÁ¤ Àå±â¸¦ Ç¥ÀûÀ¸·Î »ï´Â °æ¿ìµµ ÀÖ½À´Ï´Ù. ¼¼°è¿¡¼­ Àü½Å¼º È«¹Ý¼º ·çǪ½º, ·ù¸¶Æ¼½º °üÀý¿° µî ¾à 80¿© Á¾ÀÇ ÀÚ°¡¸é¿ªÁúȯÀÌ Á¸ÀçÇÕ´Ï´Ù. ¹Ì±¹ ÀÚ°¡¸é¿ªÁúȯÇùȸ(AARDA)¿¡ µû¸£¸é 5,000¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ ÀÚ°¡¸é¿ªÁúȯÀ» ¾Î°í ÀÖÀ¸¸ç, ±× Áß 75%°¡ ¿©¼ºÀÔ´Ï´Ù. ÀÚ°¡¸é¿ªÁúȯ Áø´Ü °Ë»ç¿¡´Â ÀÚ°¡Ç×ü °Ë»ç, Ç×ÇÙÇ×ü °Ë»ç, ÀüÇ÷±¸ °è»ê, C¹ÝÀÀ¼º ´Ü¹éÁú, ÀûÇ÷±¸ ħ°­¼Óµµ µîÀÌ Æ÷ÇԵ˴ϴÙ.

ÁÖ¿ä ½ÃÀå ÃËÁø¿äÀÎ

ÀÚ°¡¸é¿ªÁúȯ¿¡ ´ëÇÑ ÀǽÄÀÇ Çâ»ó

½ÃÀå °³¿ä
¿¹Ãø ±â°£ 2024-2028³â
2022³â ½ÃÀå ±Ô¸ð 50¾ï 2,000¸¸ ´Þ·¯
2028³â ½ÃÀå ±Ô¸ð 72¾ï 8,000¸¸ ´Þ·¯
CAGR 2023-2028³â 6.37%
±Þ¼ºÀå ºÎ¹® ·ù¸¶Æ¼½º °üÀý¿°
ÃÖ´ë ½ÃÀå ºÏ¹Ì

½ºÆ®·¹½º, À¯ÀüÀÚ µ¹¿¬º¯ÀÌ, ºÒ°Ç°­ÇÑ ½Ä½À°ü, ȯ°æÀû ¿äÀÎÀÌ ÀÚ°¡¸é¿ªÁúȯÀÇ ¹ßº´¿¡ Å« ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ÀÚ°¡¸é¿ªÁúȯÀÌ ¼¼°è¿¡¼­ À¯ÇàÇϸ鼭 ÀÚ°¡¸é¿ªÁúȯ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2020³â CDC National Diabetes Statistics Report¿¡ µû¸£¸é ¾à 140¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ Á¦1Çü ´ç´¢º´À» ¾Î°í ÀÖÀ¸¸ç, 2040³â¿¡´Â 210¸¸ ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °ø°ø ±â°ü°ú ¹Î°£ ´ÜüÀÇ ÀÎ½Ä °³¼± Ȱµ¿Àº ÀÚ°¡¸é¿ªÁúȯ¿¡ ´ëÇÑ Áö½Ä Çâ»ó¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ÀÚ°¡¸é¿ªÇùȸ(Autoimmune Association)¿Í °°Àº ´Üü´Â ÀÌ·¯ÇÑ Áúȯ¿¡ ´ëÇÑ Á¤º¸¸¦ ³Î¸® ¾Ë¸®±â À§ÇØ ÀÎ½Ä °³¼± Ä·ÆäÀÎÀ» ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ÀÚ°¡¸é¿ªÁúȯÀÇ Á¶±â Áø´ÜÀº Àå¾Ö, ÀÌȯÀ² ¹× »ç¸Á·üÀ» ÃÖ¼ÒÈ­ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇϸç, ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

ÀÚ°¡¸é¿ª Áúȯ ¹ß»ý·ü Áõ°¡

¿°Áõ¼º Àå Áúȯ(IBD), ·ù¸¶Æ¼½º °üÀý¿°°ú °°Àº ÀÚ°¡¸é¿ªÁúȯÀÇ À¯º´·ü Áõ°¡´Â ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ȯÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó Á¶±â ¹ß°ß ¹× Áø´Ü¿¡ ´ëÇÑ Á߿伺ÀÌ Ä¿Áö°í ÀÖ½À´Ï´Ù. Àû½Ã¿¡ Áø´ÜÇÏ´Â °ÍÀº ÀûÀýÇÑ Ä¡·á ¹× °ü¸® Àü·«À» ½ÃÀÛÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ´Ù¾çÇÑ ÀÚ°¡¸é¿ªÁúȯÀÇ ³ôÀº ¹ßº´·ü·Î ÀÎÇØ À̵é ÁúȯÀ» Á¤È®ÇÏ°Ô °¨º°ÇÒ ¼ö ÀÖ´Â ´Ù¾çÇÑ Áø´Ü °Ë»ç°¡ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ´Ù¾çÇÑ Áúº´ ¾ç»ó¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â Á¾ÇÕÀûÀÎ Áø´Ü ŸŶ¿¡ ´ëÇÑ ¼ö¿ä¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Áø´Ü±â¼úÀÇ Çâ»ó

±â¼úÀÇ ¹ßÀüÀ¸·Î ¿©·¯ °³ÀÇ ÀÚ°¡ Ç×ü¸¦ µ¿½Ã¿¡ ½Äº°Çϰí ÃøÁ¤ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Ç׿ø ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ¹× Áú·® ºÐ¼®°ú °°Àº ±â¼úÀº ÀÚ°¡ ¸é¿ª Áúȯ°ú °ü·ÃµÈ ƯÁ¤ Ç×ü ¹× ¹ÙÀÌ¿À¸¶Ä¿¸¦ °¨ÁöÇÏ´Â ¹Î°¨µµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº º¸´Ù Á¤È®Çϰí Á¶±â ¹ß°ßÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ½ÇÇè½Ç ÀÚµ¿È­¿Í ±âÁ¸ ±â¼úÀÇ ´ëü´Â ¼¼°è ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå °úÁ¦

´Ù¾çÇÑ Áø´Ü°Ë»çÀÇ Çʿ伺°ú ¼Ò¿ä½Ã°£ÀÇ Àå±âÈ­

ÀÚ°¡¸é¿ªÁúȯÀÇ °ËÃâÀº ½Ã°£ÀÌ ¿À·¡ °É¸®¸ç, ·ù¸¶Æ¼½º°üÀý¿°, ¾Öµð½¼º´, ÇϽøðÅ亴ÀÇ Ç÷û°Ë»ç¿Í °°Àº ´Ù¾çÇÑ °Ë»ç ½Ã³ª¸®¿À¸¦ Æ÷ÇÔÇÕ´Ï´Ù. ƯÁ¤ ÀÚ°¡¸é¿ªÁúȯÀ» ³ôÀº Á¤È®µµ·Î È®½ÇÇÏ°Ô °ËÃâÇÒ ¼ö ÀÖ´Â ´ÜÀÏ °Ë»ç°¡ ¾ø±â ¶§¹®¿¡ ¿©·¯ °¡Áö ÀÓ»ó °Ë»ç°¡ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç¿¡´Â ¿ÏÀüÇÑ ´ë»ç ÆÐ³Î, Ç÷±¸ ¼ö º¸°í, Ç÷û °Ë»ç, À¯¼¼Æ÷ ºÐ¼®, HLA ŸÀÌÇÎ µîÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ °Ë»ç¿¡ ¼Ò¿äµÇ´Â ½Ã°£ÀÌ ±æ¾î ºü¸¥ Áø´Ü¿¡ ¹æÇذ¡ µË´Ï´Ù. ¶ÇÇÑ °í°¡ÀÇ °Ë»ç ºñ¿ë°ú ÀçÁ¤ÀÇ ¹®Á¦µµ ¹®Á¦ÀÔ´Ï´Ù. ¼÷·ÃµÈ Àü¹®°¡ÀÇ ºÎÁ·µµ ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

°³¹ßµµ»ó±¹¿¡¼­ÀÇ Á¦ÇÑÀû º¸±Þ

ÀÚ°¡¸é¿ªÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÏ´Â Ãß¼¼ÀÌÁö¸¸, Á¦Ç° º¸±ÞÀÌ Á¦ÇÑÀûÀ̱⠶§¹®¿¡ ½ÃÀå È®´ë¿¡ ÇѰ谡 ÀÖ½À´Ï´Ù. ½ÅÈï ±¹°¡ ½ÃÀå¿¡¼­´Â IBD¿Í °°Àº ½ÅÈï Áúȯ¿¡ ´ëÇÑ °¨½Ã¿Í µ¥ÀÌÅͺ£À̽º°¡ ºÎÁ·ÇÕ´Ï´Ù. ¿ªÇÐ µ¥ÀÌÅÍ¿Í È¿À²ÀûÀÎ Áø´Ü ¹æ¹ý¿¡ ´ëÇÑ Á¢±Ùµµ Á¦ÇÑÀûÀÔ´Ï´Ù. ³·Àº ÀÎÁöµµ´Â ¿¹¾àÀÇ °É¸²µ¹·Î ÀÛ¿ëÇØ ½ÅÈï ±¹°¡ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀ嵿Çâ

Çõ½ÅÀû ÀÚ°¡¸é¿ªÁúȯ ŽÁö Á¢±Ù¹æ½Ä

Á¤È®ÇÑ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä°¡ °æÀï ±¸µµ¸¦ ÃËÁøÇÏ°í ½Å±Ô ÁøÀÔÀ» ÃËÁøÇÕ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¹Ì°³¹ßµÈ ¼ºÀå°ú ȯÀÚ ¼ö Áõ°¡·Î ÀÎÇØ ÀáÀçÀû ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ¿¬±¸¿Í ±³À°Àº ¸ÅÃâ âÃâÀÇ ±âȸ¸¦ Á¦°øÇϰí, ±³À° Ȱµ¿Àº µ¶ÀÚÀûÀÎ Áø´Ü ±â¼úÀ» °³¹ßÇÒ ¼ö ÀÖ´Â ¿©Áö¸¦ Á¦°øÇÕ´Ï´Ù. ÀÚµ¿È­¿Í ±âÁ¸ ±â¼úÀÇ ´ëü°¡ ½ÃÀå È®´ë¿¡ ±â¿©ÇÕ´Ï´Ù.

POC¿Í ÀçÅà °Ë»ç

°£ÆíÇÏ°í ºü¸¥ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä´Â ÇöÀå Áø·á ¹× °¡Á¤¿ë °Ë»ç ŰƮÀÇ °³¹ßÀ» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ȯÀÚ´Â ÀÚ½ÅÀÇ »óŸ¦ ½±°Ô ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ°í, ½Å¼ÓÇÑ Ä¡·á ¹æÄ§À» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. °¡Á¤ °Ë»ç´Â ÀÇ·á ½Ã¼³ÀÇ ºÎ´ãÀ» ÁÙÀ̰í ȯÀÚ°¡ ÀÇ·á¿¡¼­ º¸´Ù Àû±ØÀûÀÎ ¿ªÇÒÀ» ÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù.

ºÎ¹®º° ÀλçÀÌÆ®

Áúº´ÀÇ À¯Çü

±¹¼Ò Áúȯ Áø´ÜÀº °Ë»ç °Ç¼ö°¡ ¸¹°í ȯÀÚµéÀÇ ÀνÄÀÌ »ó´ëÀûÀ¸·Î ³ô¾Æ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. Àü½Å Áúȯ Áø´ÜÀº Á¤ºÎÀÇ Àû±ØÀûÀÎ ³ë·Â°ú ÀÎ½Ä °³¼±À¸·Î ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¦Ç°

½Ã¾à, ºÐ¼® ¹× ŰƮ ºÐ¾ß´Â ¼±Áø±¹ÀÇ ³ôÀº Áø´ÜÀ²°ú Á¤±âÀûÀÎ ±¸¸Å·Î ÀÎÇØ 2023³â±îÁö °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Áö¿ªº° ÀλçÀÌÆ®

¾Æ½Ã¾ÆÅÂÆò¾ç

¾Æ½Ã¾ÆÅÂÆò¾ç¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÚ°¡¸é¿ªÁúȯÀÇ À¯º´·ü Áõ°¡, °Ç°­¿¡ ÇØ·Î¿î »ýȰ½À°ü, Á¤ºÎÀÇ ±¸»ó°ú ¿¬±¸ ÅõÀÚ·Î ÀÎÇØ ³ôÀº ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀεµÀÇ °Ç¼± ȯÀÚ´Â Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â ÀÌ Áö¿ªÀÇ À¯º´·ü Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

°á·Ð

/h4

¼¼°è ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀåÀº ÀÎ½Ä °³¼±, ÀÚ°¡¸é¿ªÁúȯ À¯º´·ü Áõ°¡, Áø´Ü °³¼±, Çõ½ÅÀû Á¢±Ù¹æ½ÄÀ¸·Î ÀÎÇØ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. µµÀü°úÁ¦·Î´Â ¿©·¯ °Ë»çÀÇ Çʿ伺, ±ä °Ë»ç ½Ã°£, °³¹ßµµ»ó±¹¿¡¼­ÀÇ º¸±Þ ÇѰè, ¼÷·ÃµÈ Àü¹®°¡ ºÎÁ· µîÀÌ ²ÅÈü´Ï´Ù. Æ®·»µå¿¡´Â Çõ½ÅÀû °ËÃâ ¹æ¹ý, ÇöÀå Áø·á/°¡Á¤³» °Ë»ç µîÀÌ ÀÖ½À´Ï´Ù. Áúº´ À¯Çü, Á¦Ç°, Áö¿ªÀû ¿äÀÎÀÌ ½ÃÀå ¿ªÇп¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÚ°¡¸é¿ªÁúȯÀÇ È®»êÀ¸·Î ÀÎÇØ ÀáÀçÀûÀÎ ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀåÀº Á¶±â Áø´Ü ¹× °Ë»ç ±â¼ú Çâ»ó¿¡ ÁßÁ¡À» µÎ°í ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå °í°´ÀÇ ¼Ò¸®

Á¦5Àå ¼¼°èÀÇ ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø
    • ±Ý¾×º°
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
    • Á¦Ç°º°(½Ã¾à, ŰƮ, ¾î¼¼ÀÌ, ±â±â)
    • °Ë»ç À¯Çüº°(Ç×ÇÙÇ×ü °Ë»ç, ÀÚ°¡Ç×ü°Ë»ç, CRP, ÀüÇ÷±¸ »êÁ¤, ¿ä°Ë»ç)
    • Áúȯ À¯Çüº°(Àü½Å¼º, ±¹¼Ò¼º)
    • ÃÖÁ¾»ç¿ëÀÚº°(º´¿ø, Áø´Ü ·¦, ¿¬±¸±â°ü)
    • Áö¿ªº°
    • ±â¾÷º°(2022³â)
  • ½ÃÀå ¸Ê

Á¦6Àå ºÏ¹ÌÀÇ ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø
    • ±Ý¾×º°
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
    • Á¦Ç°º°
    • °Ë»ç À¯Çüº°
    • Áúȯ À¯Çüº°
    • ÃÖÁ¾»ç¿ëÀÚº°
    • ±¹°¡º°
  • ºÏ¹Ì : ±¹°¡º° ºÐ¼®
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ

Á¦7Àå À¯·´ÀÇ ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø
    • ±Ý¾×º°
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
    • Á¦Ç°º°
    • °Ë»ç À¯Çüº°
    • Áúȯ À¯Çüº°
    • ÃÖÁ¾»ç¿ëÀÚº°
  • À¯·´ : ±¹°¡º° ºÐ¼®
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø
    • ±Ý¾×º°
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
    • Á¦Ç°º°
    • °Ë»ç À¯Çüº°
    • Áúȯ À¯Çüº°
    • ÃÖÁ¾»ç¿ëÀÚº°
  • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º° ºÐ¼®
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ

Á¦9Àå ³²¹ÌÀÇ ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø
    • ±Ý¾×º°
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
    • Á¦Ç°º°
    • °Ë»ç À¯Çüº°
    • Áúȯ À¯Çüº°
    • ÃÖÁ¾»ç¿ëÀÚº°
  • ³²¹Ì : ±¹°¡º° ºÐ¼®
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ÄÝ·Òºñ¾Æ

Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø
    • ±Ý¾×º°
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
    • Á¦Ç°º°
    • °Ë»ç À¯Çüº°
    • Áúȯ À¯Çüº°
    • ÃÖÁ¾»ç¿ëÀÚº°
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º° ºÐ¼®
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®

Á¦11Àå ½ÃÀå ¿ªÇÐ

Á¦12Àå ½ÃÀå µ¿Çâ°ú ¹ßÀü

Á¦13Àå ¼¼°èÀÇ ÀÚ°¡¸é¿ªÁúȯ Áø´Ü ½ÃÀå SWOT ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

  • Siemens Healthcare Private Limited
  • bioMerieux SA
  • Bio-rad Laboratories
  • Beckman Coulter, Inc.
  • F. Hoffmann-la Roche
  • Inova Diagnostics, Inc.
  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific
  • Trinity Biotech Plc.
  • Hemagen Diagnostics, Inc.

Á¦15Àå Àü·«Àû Á¦¾È

Á¦16Àå Á¶»çȸ»ç¡¤¸éÃ¥»çÇ×

KSA 23.11.09

The Global Autoimmune Disease Diagnostics Market was valued at USD 5.02 Billion in 2022 and is expected to exhibit strong growth throughout the forecast period, projecting a Compound Annual Growth Rate (CAGR) of 6.37% and expected to reach USD 7.28 Billion through 2028. Autoimmune disease (AD) is a non-communicable ailment characterized by the disruption of healthy immunological equilibrium, leading to aberrant reactions in affected tissue cells. Inflammation, autoantibodies, and activated T cells are pivotal in the development of autoimmune disorders. While immune cells typically recognize and combat external agents like bacteria and viruses, autoimmune diseases lead to the immune system erroneously attacking the body itself. Some autoimmune conditions specifically target particular organs. Globally, almost 80 types of autoimmune diseases exist, including systemic lupus erythematosus and rheumatoid arthritis. The American Autoimmune Related Diseases Association (AARDA) reveals that up to 50 million Americans suffer from autoimmune diseases, with females constituting 75% of the cases. Diagnostic tests for autoimmune diseases encompass autoantibody tests, antinuclear antibody tests, complete blood count, C-reactive protein, and erythrocyte sedimentation rate.

Key Market Drivers

Growing Awareness of Autoimmune Diseases

Market Overview
Forecast Period2024-2028
Market Size 2022USD 5.02 Billion
Market Size 2028USD 7.28 Billion
CAGR 2023-20286.37%
Fastest Growing SegmentRheumatoid Athritis
Largest MarketNorth America

Stress, genetic mutations, unhealthy eating habits, and environmental factors contribute significantly to autoimmune disease development. The global prevalence of autoimmune diseases has led to an increased demand for autoimmune disease diagnostics. For instance, the 2020 CDC National Diabetes Statistics Report states that approximately 1.4 million Americans have Type-1 diabetes, with projections indicating a rise to 2.1 million by 2040. Heightened awareness efforts by public and private organizations have contributed to increased knowledge of autoimmune diseases. Organizations like the Autoimmune Association (U.S.) conduct awareness campaigns to disseminate information about these disorders. Early autoimmune disease diagnosis is pivotal in minimizing disability, morbidity, and mortality rates, driving the autoimmune disease diagnostics market's growth.

Increasing Incidence of Autoimmune Diseases

The increasing prevalence of autoimmune diseases, such as Inflammatory Bowel Disease (IBD) and rheumatoid arthritis, is expected to significantly impact the autoimmune disease diagnostics market. As more individuals are affected, there is a greater emphasis on early detection and diagnosis. This timely diagnosis is crucial for initiating appropriate treatment and management strategies. The higher incidence of different autoimmune diseases necessitates a diverse array of diagnostic tests that can accurately differentiate between these conditions. These developments contribute to the demand for a comprehensive diagnostic toolkit to address diverse disease presentations.

Improvement in Diagnostic Techniques

Technological advancements have enabled the simultaneous identification and measurement of multiple autoantibodies. Techniques like antigen microarrays and mass spectrometry offer increased sensitivity in detecting specific antibodies or biomarkers associated with autoimmune diseases. These advancements allow for more precise and early detection. Automation of laboratories and the replacement of conventional technologies contribute to the expansion of the global autoimmune disease diagnostics market.

Key Market Challenges

Need for Multiple Diagnostic Tests and Prolonged Turnaround Time

Detecting autoimmune diseases is time-consuming, involving various testing scenarios like serum testing for rheumatoid arthritis, Addison's disease, and Hashimoto's disease. Multiple laboratory tests are necessary due to no single test reliably detecting a specific autoimmune disease with high accuracy. These tests may include a complete metabolic panel, blood count report, serologies, flow cytometry, and HLA typing. Turnaround times for these tests can be extended, impeding prompt diagnosis. Moreover, high test costs and reimbursement issues are challenges. The lack of skilled professionals also impacts the market.

Limited Penetration in Developing Regions

While autoimmune diseases' prevalence is rising, limited product penetration restricts market expansion. Developing markets lack surveillance and databases for emerging diseases like IBD. Epidemiological data and access to efficient diagnostics are limited. Lack of awareness hampers appointments, impeding market growth in emerging countries.

Key Market Trends

Innovative Autoimmune Disease Detection Approaches

The demand for accurate diagnosis fosters a competitive landscape, encouraging new players. Competitive pricing among established leaders is encouraged, and the Asia-Pacific region offers potential due to untapped growth and an expanding patient population. Research studies present revenue opportunities, and awareness efforts create room for unique diagnostic techniques' development. Automation and conventional technology replacement contribute to market expansion.

Point-of-Care and Home Testing

Demand for convenient and rapid diagnostics could drive point-of-care and home testing kits' development. Patients can monitor their conditions conveniently, aiding quicker treatment decisions. Home testing reduces healthcare facility burden and allows patients to play a more active role in their healthcare.

Segmental Insights

Disease Type

Localized disease diagnostics dominated the market due to large procedure volumes and relatively higher patient awareness. Systemic disease diagnostics are projected to grow rapidly, fueled by favorable government initiatives and increased awareness.

Product

The reagents, assays, and kits segment is expected to hold the largest market share by 2023, driven by high diagnosis rates and recurring purchases in developed countries.

Regional Insights

Asia-Pacific

The Asia-Pacific region is poised for high growth due to increasing autoimmune disease prevalence, unhealthy lifestyles, government initiatives, and research investments. Psoriasis cases in India are projected to rise, contributing to the region's growing prevalence.

Conclusion

The Global Autoimmune Disease Diagnostics Market is experiencing growth due to rising awareness, increasing autoimmune disease incidence, diagnostic improvements, and innovative approaches. Challenges include the need for multiple tests, extended turnaround time, limited penetration in developing regions, and a shortage of skilled professionals. Trends include innovative detection methods and point-of-care/home testing. Disease type, product, and regional factors are influencing market dynamics. The Asia-Pacific region holds potential due to expanding autoimmune disease prevalence. Overall, the autoimmune disease diagnostics market is set to grow with a focus on early diagnosis and improved testing techniques.

Key Market Players

  • Siemens Healthcare Private Limited
  • bioMerieux SA
  • Bio-rad Laboratories
  • Beckman Coulter, Inc.
  • F. Hoffmann-la Roche
  • Inova Diagnostics, Inc.
  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific
  • Trinity Biotech Plc.
  • Hemagen Diagnostics, Inc.

Report Scope:

In this report, the Global Autoimmune Disease Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Autoimmune Disease Diagnostics Market, By Product:

  • Reagents
  • Kits
  • Assays
  • Instruments

Autoimmune Disease Diagnostics Market, By Test Type:

  • Antinuclear Antibody Tests
  • Autoantibody Tests
  • C-reactive Protein
  • Complete Blood Count
  • Urinalysis

Autoimmune Disease Diagnostics Market, By Disease Type:

  • Systemic
  • Localized

Autoimmune Disease Diagnostics Market, By End User:

  • Hospitals
  • Diagnostic Labs
  • Research Institutes

Autoimmune Disease Diagnostics Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Autoimmune Disease Diagnostics Market.

Available Customizations:

  • Global Autoimmune Disease Diagnostics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Autoimmune Disease Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Reagents, Kits, Assays, Instruments)
    • 5.2.2. By Test Type (Antinuclear Antibody Tests, Autoantibody Tests, C-reactive Protein, Complete Blood Count, Urinalysis)
    • 5.2.3. By Disease Type (Systemic, Localized)
    • 5.2.4. By End User (Hospitals, Diagnostic Labs, Research Institutes),
    • 5.2.5. By Region
    • 5.2.6. By Company (2022)
  • 5.3. Market Map

6. North America Autoimmune Disease Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Test Type
    • 6.2.3. By Disease Type
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Autoimmune Disease Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Test Type
        • 6.3.1.2.3. By Disease Type
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Autoimmune Disease Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Test Type
        • 6.3.2.2.3. By Disease Type
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Autoimmune Disease Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Test Type
        • 6.3.3.2.3. By Disease Type
        • 6.3.3.2.4. By End User

7. Europe Autoimmune Disease Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Test Type
    • 7.2.3. By Disease Type
    • 7.2.4. By End User
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Autoimmune Disease Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Test Type
        • 7.3.1.2.3. By Disease Type
        • 7.3.1.2.4. By End User
    • 7.3.2. United Kingdom Autoimmune Disease Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Test Type
        • 7.3.2.2.3. By Disease Type
        • 7.3.2.2.4. By End User
    • 7.3.3. Italy Autoimmune Disease Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Test Type
        • 7.3.3.2.3. By Disease Type
        • 7.3.3.2.4. By End User
    • 7.3.4. France Autoimmune Disease Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Test Type
        • 7.3.4.2.3. By Disease Type
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Autoimmune Disease Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Test Type
        • 7.3.5.2.3. By Disease Type
        • 7.3.5.2.4. By End User

8. Asia-Pacific Autoimmune Disease Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Test Type
    • 8.2.3. By Disease Type
    • 8.2.4. By End User
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Autoimmune Disease Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Test Type
        • 8.3.1.2.3. By Disease Type
        • 8.3.1.2.4. By End User
    • 8.3.2. India Autoimmune Disease Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Test Type
        • 8.3.2.2.3. By Disease Type
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Autoimmune Disease Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Test Type
        • 8.3.3.2.3. By Disease Type
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Autoimmune Disease Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Test Type
        • 8.3.4.2.3. By Disease Type
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Autoimmune Disease Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Test Type
        • 8.3.5.2.3. By Disease Type
        • 8.3.5.2.4. By End User

9. South America Autoimmune Disease Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Test Type
    • 9.2.3. By Disease Type
    • 9.2.4. By End User
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Autoimmune Disease Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Test Type
        • 9.3.1.2.3. By Disease Type
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Autoimmune Disease Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Test Type
        • 9.3.2.2.3. By Disease Type
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Autoimmune Disease Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Test Type
        • 9.3.3.2.3. By Disease Type
        • 9.3.3.2.4. By End User

10. Middle East and Africa Autoimmune Disease Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Test Type
    • 10.2.3. By Disease Type
    • 10.2.4. By End User
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Autoimmune Disease Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Test Type
        • 10.3.1.2.3. By Disease Type
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Autoimmune Disease Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Test Type
        • 10.3.2.2.3. By Disease Type
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Autoimmune Disease Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Test Type
        • 10.3.3.2.3. By Disease Type
        • 10.3.3.2.4. By End User

11. Market Dynamics

12. Market Trends & Developments

13. Global Autoimmune Disease Diagnostics Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Services Offerings
  • 14.3. Recent Developments
  • 14.4. Key Personnel
  • 14.5. SWOT Analysis
    • 14.5.1. Siemens Healthcare Private Limited
    • 14.5.2. bioMerieux SA
    • 14.5.3. Bio-rad Laboratories
    • 14.5.4. Beckman Coulter, Inc.
    • 14.5.5. F. Hoffmann-la Roche
    • 14.5.6. Inova Diagnostics, Inc.
    • 14.5.7. Myriad Genetics, Inc.
    • 14.5.8. Thermo Fisher Scientific
    • 14.5.9. Trinity Biotech Plc.
    • 14.5.10. Hemagen Diagnostics, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦